Dr. Guifang Guo 郭桂芳
Chief Physician
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology for colorectal cancer and lung cancer, including chemotherapy and targeted therapy.
Dr. Guo holds a PhD in Oncology from Sun Yat-sen University Cancer Center. Training includes a clinical medicine degree from Wannan Medical College and residency at Taiyuan Coal Mining Group General Hospital. Since 2004, Dr. Guo has worked at Sun Yat-sen University Cancer Center, focusing on medical oncology. Research interests include new anti-tumor and targeted drugs. Dr. Guo has published over 30 papers and leads provincial research projects.
Professional roles
- Vice Chair, Comprehensive Tumor Therapy Branch, Guangdong Precision Medicine Application Society
- Vice Chair, Head and Neck Tumor Branch, Guangdong Precision Medicine Application Society
- Member, Tumor Targeted Therapy Professional Committee, China Anti-Cancer Association
- Member, Tumor Clinical Chemotherapy Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Guo Guifang). Papers usually list the name as Guifang Guo or Guo G.
Selected publications
53 papers on PubMed matched by name and affiliation; 23 as first or senior author since 2016. Most recent first- or senior-author papers:
- Immunotargets Ther, 2025 (senior author): Efficacy and Safety of Different Sequences for mFOLFIRINOX (or SOXIRI) and Gemcitabine Plus Albumin-Bound Paclitaxel in Unresectable Pancreatic Cancer. PubMed 41058852
- Clin Transl Oncol, 2025 (senior author): Predictive significance of MPT-driven necrosis-related genes signature in gastric cancer and their impact on the tumor microenvironment. PubMed 39690336
- Front Immunol, 2025 (senior author): Comprehensive analysis of the functional and immunological significance of ETV4 in pan-cancer and its validation in digestive tumors. PubMed 40469297
- Hepatol Commun, 2025 (senior author): EBV enhances immunotherapy sensitivity in intrahepatic cholangiocarcinoma through cGAS-STING pathway activation. PubMed 40079734
- Hepatol Int, 2025 (senior author): What is the truth: the roles of macrophages in EBV-LELCC. PubMed 39369137
- Front Pharmacol, 2024 (senior author): Anatomical classification of advanced biliary tract cancer predicts programmed cell death protein 1 blockade efficacy. PubMed 39281274
- Pancreatology, 2024 (senior author): Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal adenocarcinoma. PubMed 38195328
- Ther Adv Med Oncol, 2023 (senior author): Efficacy and safety of SOXIRI versus mFOLFIRINOX in advanced pancreatic cancer. PubMed 37435561
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion